FR2413974A1
(fr)
|
1978-01-06 |
1979-08-03 |
David Bernard |
Sechoir pour feuilles imprimees par serigraphie
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4703004A
(en)
|
1984-01-24 |
1987-10-27 |
Immunex Corporation |
Synthesis of protein with an identification peptide
|
WO1986005807A1
(en)
|
1985-04-01 |
1986-10-09 |
Celltech Limited |
Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2, Inc., Danville, Calif. |
Geänderte antikörper.
|
US5750172A
(en)
|
1987-06-23 |
1998-05-12 |
Pharming B.V. |
Transgenic non human mammal milk
|
GB8717430D0
(en)
|
1987-07-23 |
1987-08-26 |
Celltech Ltd |
Recombinant dna product
|
US5336603A
(en)
|
1987-10-02 |
1994-08-09 |
Genentech, Inc. |
CD4 adheson variants
|
IL106992A
(en)
|
1988-02-11 |
1994-06-24 |
Bristol Myers Squibb Co |
Noble hydrazonic history of anthracycline and methods for their preparation
|
US5879936A
(en)
|
1988-04-18 |
1999-03-09 |
Aluguisse Holding A.G. |
Recombinant DNA methods, vectors and host cells
|
GB8809129D0
(en)
|
1988-04-18 |
1988-05-18 |
Celltech Ltd |
Recombinant dna methods vectors and host cells
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
KR900005995A
(ko)
|
1988-10-31 |
1990-05-07 |
우메모또 요시마사 |
변형 인터류킨-2 및 그의 제조방법
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
WO1991000360A1
(en)
|
1989-06-29 |
1991-01-10 |
Medarex, Inc. |
Bispecific reagents for aids therapy
|
US5112946A
(en)
|
1989-07-06 |
1992-05-12 |
Repligen Corporation |
Modified pf4 compositions and methods of use
|
FR2650598B1
(fr)
|
1989-08-03 |
1994-06-03 |
Rhone Poulenc Sante |
Derives de l'albumine a fonction therapeutique
|
WO1991006570A1
(en)
|
1989-10-25 |
1991-05-16 |
The University Of Melbourne |
HYBRID Fc RECEPTOR MOLECULES
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
US5633076A
(en)
|
1989-12-01 |
1997-05-27 |
Pharming Bv |
Method of producing a transgenic bovine or transgenic bovine embryo
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US5314995A
(en)
|
1990-01-22 |
1994-05-24 |
Oncogen |
Therapeutic interleukin-2-antibody based fusion proteins
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
US5349053A
(en)
|
1990-06-01 |
1994-09-20 |
Protein Design Labs, Inc. |
Chimeric ligand/immunoglobulin molecules and their uses
|
ATE204902T1
(de)
|
1990-06-29 |
2001-09-15 |
Large Scale Biology Corp |
Melaninproduktion durch transformierte mikroorganismen
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
AU665190B2
(en)
|
1990-07-10 |
1995-12-21 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
DE69127627T2
(de)
|
1990-08-29 |
1998-02-19 |
Genpharm Int |
Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
|
ES2113940T3
(es)
|
1990-12-03 |
1998-05-16 |
Genentech Inc |
Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
|
EP0517895B1
(en)
|
1990-12-14 |
1996-11-20 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
AU1545692A
(en)
|
1991-03-01 |
1992-10-06 |
Protein Engineering Corporation |
Process for the development of binding mini-proteins
|
CA2108147C
(en)
|
1991-04-10 |
2009-01-06 |
Angray Kang |
Heterodimeric receptor libraries using phagemids
|
DE4122599C2
(de)
|
1991-07-08 |
1993-11-11 |
Deutsches Krebsforsch |
Phagemid zum Screenen von Antikörpern
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
US5667988A
(en)
|
1992-01-27 |
1997-09-16 |
The Scripps Research Institute |
Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
FR2686901A1
(fr)
|
1992-01-31 |
1993-08-06 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
|
US5447851B1
(en)
|
1992-04-02 |
1999-07-06 |
Univ Texas System Board Of |
Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
|
ZA932522B
(en)
|
1992-04-10 |
1993-12-20 |
Res Dev Foundation |
Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
|
EP0656064B1
(en)
|
1992-08-17 |
1997-03-05 |
Genentech, Inc. |
Bispecific immunoadhesins
|
CA2141602A1
(en)
|
1992-08-26 |
1994-03-03 |
Philip Leder |
Use of the cytokine ip-10 as an anti-tumor agent
|
DK0669836T3
(da)
|
1992-11-13 |
1996-10-14 |
Idec Pharma Corp |
Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
|
US7744877B2
(en)
|
1992-11-13 |
2010-06-29 |
Biogen Idec Inc. |
Expression and use of anti-CD20 Antibodies
|
DK0804070T3
(da)
|
1993-03-09 |
2000-08-07 |
Genzyme Corp |
Fremgangsmåde til isolering af proteiner fra mælk
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
US5827690A
(en)
|
1993-12-20 |
1998-10-27 |
Genzyme Transgenics Corporatiion |
Transgenic production of antibodies in milk
|
NZ292124A
(en)
|
1994-07-29 |
1998-10-28 |
Smithkline Beecham Plc |
Il-4 antagonist comprising a fusion of a mutant il-4-antibody fragment
|
US6046037A
(en)
|
1994-12-30 |
2000-04-04 |
Hiatt; Andrew C. |
Method for producing immunoglobulins containing protection proteins in plants and their use
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
EP0859841B1
(en)
|
1995-08-18 |
2002-06-19 |
MorphoSys AG |
Protein/(poly)peptide libraries
|
WO1997023243A1
(en)
|
1995-12-22 |
1997-07-03 |
Bristol-Myers Squibb Company |
Branched hydrazone linkers
|
AU5711196A
(en)
|
1996-03-14 |
1997-10-01 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule i
|
CA2249195A1
(en)
|
1996-03-18 |
1997-09-25 |
Board Of Regents, The University Of Texas System |
Immunoglobin-like domains with increased half lives
|
EP0904278A4
(en)
|
1996-03-22 |
1999-09-15 |
Human Genome Sciences Inc |
MOLECULE II INDUCER OF APOPTOSIS
|
AU736549B2
(en)
|
1997-05-21 |
2001-08-02 |
Merck Patent Gesellschaft Mit Beschrankter Haftung |
Method for the production of non-immunogenic proteins
|
KR20010031713A
(ko)
|
1997-11-03 |
2001-04-16 |
벤슨 로버트 에이치. |
맥관형성 및 종양 성장 억제제인 맥관 내피 세포 성장억제제
|
JP4460155B2
(ja)
|
1997-12-05 |
2010-05-12 |
ザ・スクリプス・リサーチ・インステイチユート |
マウス抗体のヒト化
|
GB9818731D0
(en)
|
1998-08-27 |
1998-10-21 |
Univ Portsmouth |
Compounds
|
ATE294803T1
(de)
|
1998-08-27 |
2005-05-15 |
Spirogen Ltd |
Pyrrolobenzodiazepine
|
CA2342967A1
(en)
|
1998-12-08 |
2000-06-15 |
Biovation Limited |
Modifying protein immunogenicity
|
KR101077001B1
(ko)
|
1999-01-15 |
2011-10-26 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US20040067490A1
(en)
|
2001-09-07 |
2004-04-08 |
Mei Zhong |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
EP1276756A4
(en)
|
2000-04-12 |
2004-06-09 |
Human Genome Sciences Inc |
ALBUMIN FUSION PROTEINS
|
EP1290026A2
(en)
|
2000-04-28 |
2003-03-12 |
Eli Lilly And Company |
Human sez6 nucleic acids and polypeptides
|
US7138496B2
(en)
|
2002-02-08 |
2006-11-21 |
Genetastix Corporation |
Human monoclonal antibodies against human CXCR4
|
US7608704B2
(en)
|
2000-11-08 |
2009-10-27 |
Incyte Corporation |
Secreted proteins
|
EP1355919B1
(en)
|
2000-12-12 |
2010-11-24 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
US6362331B1
(en)
|
2001-03-30 |
2002-03-26 |
Council Of Scientific And Industrial Research |
Process for the preparation of antitumor agents
|
US20030211991A1
(en)
|
2001-04-17 |
2003-11-13 |
Su Eric Wen |
Human sez6 nucleic acids and polypeptides
|
CN1343774A
(zh)
|
2001-05-28 |
2002-04-10 |
复旦大学 |
一种癫痫相关蛋白编码序列,其编码的多肽、制法及用途
|
AU2002357060A1
(en)
|
2001-12-03 |
2003-06-17 |
Abgenix, Inc. |
Antibody categorization based on binding characteristics
|
JP2005533001A
(ja)
|
2002-03-04 |
2005-11-04 |
メディミューン,インコーポレーテッド |
インテグリンαvβ3アンタゴニストを他の物質と併用投与する癌の予防または治療方法
|
EP2345671B8
(en)
|
2002-09-27 |
2023-01-11 |
Xencor, Inc. |
Optimized fc variants and methods for their generation
|
US20040101920A1
(en)
|
2002-11-01 |
2004-05-27 |
Czeslaw Radziejewski |
Modification assisted profiling (MAP) methodology
|
GB0226593D0
(en)
|
2002-11-14 |
2002-12-24 |
Consultants Ltd |
Compounds
|
US20050008625A1
(en)
|
2003-02-13 |
2005-01-13 |
Kalobios, Inc. |
Antibody affinity engineering by serial epitope-guided complementarity replacement
|
US7619068B2
(en)
|
2003-05-09 |
2009-11-17 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
GB0321295D0
(en)
|
2003-09-11 |
2003-10-15 |
Spirogen Ltd |
Synthesis of protected pyrrolobenzodiazepines
|
KR101520209B1
(ko)
|
2003-11-06 |
2015-05-13 |
시애틀 지네틱스, 인크. |
리간드에 접합될 수 있는 모노메틸발린 화합물
|
EP1718667B1
(en)
|
2004-02-23 |
2013-01-09 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
GB0404577D0
(en)
|
2004-03-01 |
2004-04-07 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
DK2270010T3
(da)
|
2004-03-01 |
2012-05-14 |
Spirogen Ltd |
11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-on-derivater som vigtige mellemprodukter i fremstillingen af c2-substituerede pyrrolobenzodiazepiner
|
US7189710B2
(en)
|
2004-03-30 |
2007-03-13 |
Council Of Scientific And Industrial Research |
C2-fluoro pyrrolo [2,1−c][1,4]benzodiazepine dimers
|
FR2869231B1
(fr)
|
2004-04-27 |
2008-03-14 |
Sod Conseils Rech Applic |
Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
|
CA2574881C
(en)
|
2004-08-04 |
2013-01-08 |
Amgen Inc. |
Antibodies to dkk-1
|
ES2579805T3
(es)
|
2004-09-23 |
2016-08-16 |
Genentech, Inc. |
Anticuerpos y conjugados modificados por ingeniería genética con cisteína
|
EP2298895A1
(en)
*
|
2005-07-27 |
2011-03-23 |
Oncotherapy Science, Inc. |
Method of diagnosing small cell lung cancer
|
US20070123448A1
(en)
|
2005-11-23 |
2007-05-31 |
The Hospital For Sick Children |
Novel chemical entities affecting neuroblastoma tumor-initiating cells
|
AU2006340769A1
(en)
|
2005-12-16 |
2007-10-04 |
Genentech, Inc. |
Method for diagnosing, prognosing and treating glioma
|
SI1813614T1
(sl)
|
2006-01-25 |
2012-01-31 |
Sanofi 174 |
Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate
|
EP2446904B1
(en)
|
2006-05-30 |
2015-04-29 |
Genentech, Inc. |
Anti-CD22 antibodies, their immunoconjugates and uses thereof
|
MX2008015492A
(es)
|
2006-06-06 |
2009-02-12 |
Univ Tennessee Res Foundation |
Composiciones enriquecidas en celulas madre neoplasicas y metodos que las contienen.
|
SI3207941T1
(sl)
|
2006-09-07 |
2020-08-31 |
Scott & White Memorial Hospital |
Postopki in sestavki na osnovi konjugatov toksina davice-interlevkin-3
|
US7825267B2
(en)
|
2006-09-08 |
2010-11-02 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Synthesis of FR901464 and analogs with antitumor activity
|
US8309354B2
(en)
|
2007-01-22 |
2012-11-13 |
Macrogenics West, Inc. |
Human cancer stem cells
|
WO2009012357A2
(en)
|
2007-07-17 |
2009-01-22 |
The General Hospital Corporation |
Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof
|
EP2022848A1
(en)
|
2007-08-10 |
2009-02-11 |
Hubrecht Institut |
A method for identifying, expanding, and removing adult stem cells and cancer stem cells
|
JP2010538012A
(ja)
|
2007-08-28 |
2010-12-09 |
バイオジェン アイデック マサチューセッツ インコーポレイテッド |
Igf−1rの複数のエピトープに結合する組成物
|
WO2009043051A2
(en)
|
2007-09-27 |
2009-04-02 |
Biogen Idec Ma Inc. |
Cd23 binding molecules and methods of use thereof
|
AU2009205995B2
(en)
*
|
2008-01-18 |
2014-04-03 |
Medimmune, Llc |
Cysteine engineered antibodies for site-specific conjugation
|
US8384551B2
(en)
|
2008-05-28 |
2013-02-26 |
MedHab, LLC |
Sensor device and method for monitoring physical stresses placed on a user
|
WO2010037134A2
(en)
|
2008-09-29 |
2010-04-01 |
Stemlifeline, Inc. |
Multi-stage stem cell carcinogenesis
|
WO2010081171A2
(en)
|
2009-01-12 |
2010-07-15 |
Cyntellect, Inc. |
Laser mediated sectioning and transfer of cell colonies
|
US20110020221A1
(en)
|
2009-04-09 |
2011-01-27 |
The Johns Hopkins University |
Cancer stem cell expression patterns and compounds to target cancer stem cells
|
TR201806936T4
(tr)
|
2010-01-29 |
2018-06-21 |
Chugai Pharmaceutical Co Ltd |
Anti-dll3 antikoru.
|
ES2430567T3
(es)
|
2010-04-15 |
2013-11-21 |
Spirogen Sàrl |
Pirrolobenzodiacepinas y conjugados de las mismas
|
WO2011130613A1
(en)
|
2010-04-15 |
2011-10-20 |
Seattle Genetics, Inc. |
Targeted pyrrolobenzodiazapine conjugates
|
GB201006340D0
(en)
|
2010-04-15 |
2010-06-02 |
Spirogen Ltd |
Synthesis method and intermediates
|
US8697688B2
(en)
|
2010-04-15 |
2014-04-15 |
Seattle Genetics Inc. |
Pyrrolobenzodiazepines used to treat proliferative diseases
|
EP2579897A1
(en)
|
2010-06-08 |
2013-04-17 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
WO2012012801A2
(en)
|
2010-07-23 |
2012-01-26 |
The Johns Hopkins University |
Device for capture, enumeration, and profiling of circulating tumor cells
|
CA2809864A1
(en)
|
2010-09-03 |
2012-03-08 |
Stem Centrx, Inc. |
Identification and enrichment of cell subpopulations
|
WO2013119964A2
(en)
|
2012-02-08 |
2013-08-15 |
Stem Centrx, Inc. |
Identification and enrichment of cell subpopulations
|
US20130061342A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc. |
Identification and Enrichment of Cell Subpopulations
|
US20130061340A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc. |
Identification and Enrichment of Cell Subpopulations
|
US9778264B2
(en)
|
2010-09-03 |
2017-10-03 |
Abbvie Stemcentrx Llc |
Identification and enrichment of cell subpopulations
|
CN105424942B
(zh)
|
2010-09-17 |
2017-07-18 |
国立研究开发法人产业技术综合研究所 |
肺癌鉴定标志物
|
EP2621526B1
(en)
|
2010-09-29 |
2018-06-06 |
Agensys, Inc. |
Antibody drug conjugates (adc) that bind to 191p4d12 proteins
|
EP3498303A1
(en)
|
2011-02-15 |
2019-06-19 |
ImmunoGen, Inc. |
Methods of preparation of conjugates
|
UA115030C2
(uk)
|
2011-03-02 |
2017-09-11 |
Рош Глікарт Аг |
Антитіло, яке зв'язується зі зв'язаним з мембраною карциноембріональним антигеном (сеа)
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
AU2012322934B2
(en)
|
2011-10-14 |
2016-09-08 |
Medimmune Limited |
Pyrrolobenzodiazepines
|
EP3539985A1
(en)
*
|
2012-02-24 |
2019-09-18 |
AbbVie Stemcentrx LLC |
Anti sez6 antibodies and methods of use
|
WO2015031693A1
(en)
|
2013-08-28 |
2015-03-05 |
Stem Centrx, Inc. |
Engineered anti-dll3 conjugates and methods of use
|
SG11201601424PA
(en)
|
2013-08-28 |
2016-03-30 |
Stemcentrx Inc |
Site-specific antibody conjugation methods and compositions
|
US20190209704A1
(en)
|
2014-10-20 |
2019-07-11 |
Igenica Biotherapeutics, Inc. |
Novel antibody-drug conjugates and related compounds, compositions and methods of use
|